drugset / Trial / NCT00660595

Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

NCT00660595

Phase 3 Terminated 29 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1.

Timeline

Start
2008-09
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule Oral
Comparator Risperidone Other / unclassified Oral

Indications